$1.55
0.042.65%
Last update: 7:00 AM
15 minutes delayed
Comments
Loading...
ATAI Life Sciences
ATAINASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ATAI Life Sciences (NASDAQ:ATAI) Stock, Analyst Ratings, Price Targets, Forecasts
ATAI Life Sciences NV has a consensus price target of $18.33 based on the ratings of 13 analysts. The high is $32 issued by Roth Capital on November 11, 2021. The low is $6 issued by Maxim Group on April 3, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Maxim Group, and HC Wainwright & Co. on May 17, 2024, April 3, 2024, and April 3, 2024, respectively. With an average price target of $12 between HC Wainwright & Co., Maxim Group, and HC Wainwright & Co., there's an implied 664.43% upside for ATAI Life Sciences NV from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
EF Hutton
Credit Suisse
Citigroup
1calculated from analyst ratings
Analyst Ratings for ATAI Life Sciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/21/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 05/17/2024 | Buy Now | 855.54% | HC Wainwright & Co. | Patrick Trucchio | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 282.21% | Maxim Group | Jason McCarthy | → $6 | Upgrade | Hold → Buy | Get Alert |
| 04/03/2024 | Buy Now | 855.54% | HC Wainwright & Co. | Patrick Trucchio | $20 → $15 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | $20 → $20 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 01/02/2024 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 473.32% | Credit Suisse | Judah Frommer | → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 03/31/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | 473.32% | Credit Suisse | Judah Frommer | → $9 | Reiterates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | → $15 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 473.32% | Credit Suisse | Judah Frommer | $11 → $9 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | 1174.05% | HC Wainwright & Co. | Patrick Trucchio | $50 → $20 | Maintains | Buy | Get Alert |
| 01/09/2023 | Buy Now | 537.02% | Citigroup | Neena Bitritto-Garg | $20 → $10 | Maintains | Buy | Get Alert |
| 01/06/2023 | Buy Now | 855.54% | EF Hutton | Elemer Piros | $23 → $15 | Maintains | Buy | Get Alert |
| 12/16/2022 | Buy Now | 1365.15% | EF Hutton | Elemer Piros | → $23 | Initiates | → Buy | Get Alert |
| 11/01/2022 | Buy Now | 1046.64% | Loop Capital | Esther Hong | → $18 | Initiates | → Buy | Get Alert |
| 09/01/2022 | Buy Now | 1174.05% | Citigroup | Neena Bitritto-Garg | $22 → $20 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 1301.45% | Citigroup | Neena Bitritto-Garg | $26 → $22 | Maintains | Buy | Get Alert |
| 03/31/2022 | Buy Now | 473.32% | RBC Capital | Brian Abrahams | $12 → $9 | Maintains | Sector Perform | Get Alert |
| 11/30/2021 | Buy Now | 1492.56% | Maxim Group | Michael Okunewitch | — | Initiates | → Buy | Get Alert |
| 11/22/2021 | Buy Now | 3085.12% | HC Wainwright & Co. | Patrick Trucchio | — | Maintains | Buy | Get Alert |
| 11/16/2021 | Buy Now | 1428.86% | Credit Suisse | Judah Frommer | — | Maintains | Outperform | Get Alert |
| 11/16/2021 | Buy Now | 982.94% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 11/11/2021 | Buy Now | 1938.48% | Roth Capital | Elemer Piros | — | Initiates | → Buy | Get Alert |
| 10/18/2021 | Buy Now | 2448.1% | HC Wainwright & Co. | Patrick Trucchio | — | Initiates | → Buy | Get Alert |
| 09/01/2021 | Buy Now | 1619.96% | Jefferies | Andrew Tsai | — | Initiates | → Buy | Get Alert |
| 08/17/2021 | Buy Now | 1619.96% | Argus Research | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 08/17/2021 | Buy Now | 1619.96% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for ATAI Life Sciences (ATAI) stock?
The latest price target for ATAI Life Sciences (NASDAQ:ATAI) was reported by Cantor Fitzgerald on June 21, 2024. The analyst firm set a price target for $0.00 expecting ATAI to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ATAI Life Sciences (ATAI)?
The latest analyst rating for ATAI Life Sciences (NASDAQ:ATAI) was provided by Cantor Fitzgerald, and ATAI Life Sciences reiterated their overweight rating.
When was the last upgrade for ATAI Life Sciences (ATAI)?
The last upgrade for ATAI Life Sciences NV happened on April 3, 2024 when Maxim Group raised their price target to $6. Maxim Group previously had a hold for ATAI Life Sciences NV.
When was the last downgrade for ATAI Life Sciences (ATAI)?
There is no last downgrade for ATAI Life Sciences.
When is the next analyst rating going to be posted or updated for ATAI Life Sciences (ATAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ATAI Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ATAI Life Sciences was filed on June 21, 2024 so you should expect the next rating to be made available sometime around June 21, 2025.
Is the Analyst Rating ATAI Life Sciences (ATAI) correct?
While ratings are subjective and will change, the latest ATAI Life Sciences (ATAI) rating was a reiterated with a price target of $0.00 to $0.00. The current price ATAI Life Sciences (ATAI) is trading at is $1.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.